S294: MARIBAVIR (MBV) VERSUS INVESTIGATOR-ASSIGNED THERAPY FOR REFRACTORY CYTOMEGALOVIRUS (CMV) INFECTION: SUBGROUPS ANALYSES OF PHASE 3 STUDY BY RESISTANCE STATUS KNOWLEDGE REPORTED BY INVESTIGATORS.
Rafael F Duarte,
Sophie Alain,
Roy F Chemaly,
Carmen Montoto,
Isabel de Castro-Orós,
Johan Maertens,
Ignacio Tagarro
Affiliations
Rafael F Duarte
1 Hospital Universitario Puerta de Hierro, Department of Haematology, Majadahonda, Madrid, Spain
Sophie Alain
2 Limoges University Hospital, UMR Inserm 1092, University of Limoges, Department of Virology and National Reference Center for Herpesviruses, Limoges, France
Roy F Chemaly
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Carmen Montoto
4 Takeda Pharmaceuticals, Medical Department, Madrid, Spain
Isabel de Castro-Orós
4 Takeda Pharmaceuticals, Medical Department, Madrid, Spain
Johan Maertens
5 University Hospitals Leuven, KU Leuven, Haematology Department, Leuven, Belgium
Ignacio Tagarro
4 Takeda Pharmaceuticals, Medical Department, Madrid, Spain
